Background: Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD. A problem with the fecal calprotectin assays is the rather long test-turnaround times. A particle enhanced turbidimetric immunoassays (PETIA) for fecal calprotectin would reduce test-turnaround times and would permit more laboratories to perform the measurements. The aim of this study was to evaluate a new feces calprotectin PETIA.
of PETIA also for fecal calprotectin would permit more laboratories to perform the measurements with short test-turnaround times.
The aim of the present study was to validate a new PETIA for fecal calprotectin and compare the results of the assay with the Bühlmann ELISA (fCAL; MRP8/14; S100A8/A9).
| MATERIALS AND METHODS

| Samples
Anonymous leftovers from fecal samples analyzed in the routine work were used for the method validation. Frozen samples were thawed, weighted and extracted according to manufacturer's instructions. 
| Immunoparticles and reaction buffer
fCal
| Calibrators
Human calprotectin from granulocyte extracts in BÜHLMANN B-CAL-EX ™ extraction buffer was used to achieve six calibrator levels: 0, 50, 192, 468, 934 and 1862 μg/g. The calprotectin concentration of the calibrator was assigned via a value transfer protocol toward BÜHLMANN Calprotectin ELISA.
| Controls
Controls were prepared by adding human calprotectin from granulocyte extracts into BÜHLMANN B-CAL-EX ™ extraction buffer. Two levels were prepared; 75 μg/g and 250 μg/g.
| Instruments
A set of parameter settings was optimized for the Fecal Calprotectin
Immunoassay on Mindray ™ BS-380 (Mindray Medical International) and Cobas c501, Roche Diagnostics. The parameter settings are presented in Table 1 . For the method comparison, the samples were measured on both the turbidimetric fecal calprotectin immunoassay and BÜHLMANN fCAL ELISA from Bühlmann Laboratories AG, Schönenbuch, Switzerland.
| Limit of quantitation (LoQ)
Four samples at different concentration levels ranging from 10 to 25 μg/g were prepared by diluting the extracts from fecal samples (assigned with reference method, Buhlmann ELISA) with extraction buffer supplied from the manufacturer. The theoretical concentration of the diluted samples was calculated using dilution factor and assigned sample value. The diluted samples were aliquoted and frozen at −20°C. Aliquots were measured in 12 replicates during the 3 days. In total, 36 measurements for each concentration level were performed.
Coefficient of variations (CV's) and biases from theoretical values
were calculated and the total error results decided by the root mean square method. LoQ was determined to be the lowest concentration where the total error was below 20%.
| Antigen excess
A calprotectin stem solution was prepared by extracting cytosol con- The antigen excess occurs at the concentration, where the turbidimetric result of the measured sample is both lower than expected value and below the value of the highest calibrator.
| Linearity
The preparation of the linearity series was carried out by diluting a high-fecal calprotectin sample with a low fecal calprotectin sample in different concentrations, ranging from 100% to 0%. The series included eleven levels. The expected value of each level in the series was calculated from the assigned value of the high-and low-fecal calprotectin sample and the amount of high-and low sample at each level. All samples were measured in duplicates and the deviation from the expected value was calculated.
| Precision
Four samples in the range 40-1400 μg/g and two controls (Low and High) were aliquoted and stored at −20°C. Before analysis samples were thawed and immediately analyzed in duplicates. After a minimum of 2 hours, a new run of duplicate measurements were performed.
This procedure was repeated for 6 days for Cobas c501 and 20 days for BS-380. A new calibration curve was established every sixth day.
Within run, between run and between day CVs were calculated.
| Calibration curve stability
The samples used for the calibration curve stability study were prepared and stored the same way as the samples for the precision study.
On the BS-380, the set of samples were measured in triplicates twice on day 0. The mean values of each sample were used as the baseline value. For each week, a set of the samples were brought to room temperature and measured in triplicates. The mean values were compared to the baseline values and the recoveries were calculated. A recovery from baseline of 100±20% was acceptable.
When the precision study was finished on Cobas c501, the last established calibration curve was used for measuring the same set of samples for 4 more weeks in order to investigate the on-board calibration curve stability. The results were compared to the baseline values. The study failed when any of the samples had a recovery outside the range 100±20%.
| Sample carry over
The design of the sample carry over experiment follows the rec- Three samples at different levels (low, medium, high), ranging from 40 to 1100 μg/g were aliquoted and stored at −20°C. Samples were thawed and four medium samples, three low-and three high samples were analyzed in a special sequence during 5 days.
| Interference
The interference study was carried out on the BS-380 instrument only. The list of substances tested is shown in Table 2 . No interference was defined as a difference in measured concentration between test pool and control pool below 20% or below 10 μg/g.
| Method comparison
Ninety Bland test we used Analyse-it for Microsoft Excel (Leeds, UK). The
Bühlmann ELISA method was the comparative method.
| RESULTS
| Limit of quantitation
Four samples at different concentration levels ranging from 10 μg/g to 25 μg/g were analyzed during 3 days in 12 replicates. LoQ was T A B L E 2 The list of substances tested in the interference study and the effect of the addition of the tested substances on two calprotectin levels determined as the lowest concentration where the total error was below 20%. The total error for Cobas c501 was 19.6% at 20 μg/g and the total error for BS-380 was 17% at 11 μg/g.
| Antigen excess
The effects of high concentrations of calprotectin were analyzed to define antigen excess points. Obtained results indicate that antigen excess occurs at a concentration between 9400 μg/g and 14 000 μg/g for Cobas c501, and concentration between 10 000 μg/g and 16 500 μg/g for BS-380.
| Linearity
Dilution series were prepared for the instruments. The high samples and the low samples for each instrument were assigned, and the theoretical value for all levels in the series were calculated from these. The results listed in the Table 3a (Cobas c501) and b (BS-380) suggests that the assay is linear, according to the preset criteria, within the range between LoQ and the highest calibrator standard for all three instruments.
| Precision
The 6 days precision study shows that an imprecision less than 8.1%
should be expected for samples between 37.8 and 919 μg/g. On the BS-380, the imprecision of the 20 days study was observed to be less than 4.5% for all samples ranging from 49 to 1392 μg/g. For more detailed information about the imprecisions observed, see Table 4a and b.
| Calibration curve stability
The calibration curve stability study was only carried out on BS-380.
On the Cobas c501, the on-board calibration curve stability was investigated by extending the precision study 4 weeks after the last calibration. The samples measured had an acceptable recovery to baseline after 25 days, suggesting an on-board calibration curve stability of at least 25 days for the turbidimetric fecal calprotectin assay on Cobas c501. Since the reagent cassette was empty after 25 days further testing was not possible. Recovery from baseline in the range 99%-105%
implies an on-board stability significant longer than 25 days.
The samples measured at week 10 of the calibration curve stability study on the BS-380 showed a recovery between 89% and 101%. The observed calibration curve stability was in this study 10 weeks. T A B L E 3 Linearity testing of the F-calprotectin method on (a) Cobas c501 and (b) Mindray BS-380. A high sample was diluted with a low sample to achieve different F-calprotectin concentrations. The observed values were compared with the expected values and the recovery was calculated. The linearity is acceptable according to the preset criteria for the (a) Cobas c501 and (b) Mindray BS-380 in the entire range tested
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| Interference
The F-calprotectin results after addition of potentially interfering substances was compared with the original (control) F-calprotectin result.
None of the tested substances caused a clinically significant effect (defined as a difference between test and control sample of <10 μg/g or 20%) on the assay results (Table 2) .
| Method comparison
Method (Fig. 1) .
We also performed a method comparison between the turbidimetric assay on Cobas c501 and BS-380. There was a very strong correlation between the two instruments with a Passing-Bablok fit of 2.45+1.02x, Fig. 2 .
| DISCUSSION
Endoscopic evaluation with ileocolonoscopy is the gold standard for the diagnosis of IBD but the endoscopies are invasive, costly, and timeconsuming. Patients with inflammatory disorders often have elevated levels of calprotectin in blood or feces. [16] [17] [18] [19] The main clinical use of calprotectin is, however, as a fecal marker to exclude IBD. 20 Traditionally, F-calprotectin has been analyzed by ELISA using microtiter plates.
The Our study shows that the turbidimetric reagent had a good agreement with the BÜHLMANN fCAL ELISA with a slope close to 1.0. We observed no interference problems, the reagents had good stabilities and the method had a good linearity and precision on the investigated assay platforms.
In conclusion, the fCal Turbo PETIA is well suited for rapid analysis of fecal calprotectin on Mindray BS-380 or Cobas c501 analyzers providing short test turn-around times. The test results are commutable with Bühlmann fecal MRP8/14 ELISA.
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